Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

Q: What does this research mean for the field?

In patients with relapsed or refractory multiple myeloma undergoing BCMA-directed CAR T-cell therapy, bridging therapy is predominantly administered to those with more advanced and biologically adverse disease, and its efficacy varies significantly depending on the regimen used. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Marie Christine Wesener; Uta M. Demel; Thomas Pabst; Raphael Teipel; Anca‐Maria Albici; Bastian Von Tresckow; Marcel Teichert; Amelie Boquoi; Tobias Holderried; Friederike Schmitz; Fabian Müller; Friedrich-Linus Rößiger; Michele Hoffmann; Natalie Schub; Natalia Tovar; Aina Oliver-Caldes; Nicolaus Kröger; Ben‐Niklas Baermann; Stephan Bohl; David Fandrei; Vladan Vucinic; Irene Straßl; Friedrich Stölzel; Carlos Fernández de Larrea; Ulrich Keller; Antonia Busse; Maximilian Merz; Nico Gagelmann

doi:10.3324/haematol.2026.301082

Key Points

To evaluate the clinical impact, efficacy, and safety of bridging therapy administered between leukapheresis and cell infusion in patients undergoing BCMA-directed CAR T-cell therapy.
Multicenter real-world cohort study of N=399 patients with relapsed or refractory multiple myeloma receiving BCMA-directed CAR T-cell therapy.
Evaluated clinical characteristics and treatment outcomes among 348 patients (87%) who received bridging therapy compared to those who did not.
Patients receiving bridging therapy presented with more advanced, biologically aggressive disease, demonstrating higher rates of high-risk cytogenetics and penta-class refractoriness.
Disease control and response to bridging therapy differed significantly depending on the specific treatment regimen administered prior to CAR T-cell infusion.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Multicenter cohort study reveals bridging therapy efficacy varies by regimen in relapsed or refractory multiple myeloma, indicating the importance of optimizing pre-infusion disease control.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wesener et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4436b95aff0620ebc8d https://doi.org/10.3324/haematol.2026.301082

View Full Paper

Ask AI

Bookmark

Share

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading